As Duane Boise, CEO of MMJ International Holdings, recently remarked:

"Patients deserve treatments backed by science, not guesswork. If cannabinoid therapies are going to become part of modern medicine, they should meet the same standards every other drug must meet-rigorous trials, validated manufacturing, and FDA oversight."

WASHINGTON, DC / ACCESS Newswire / March 15, 2026 / As Washington prepares to launch a Medicare pilot program covering hemp-derived CBD products, a growing number of policy experts, physicians, and pharmaceutical researchers are raising a difficult question:

Are seniors about to become the largest public health experiment in cannabinoid history?

The proposal, expected to begin as early as April 2026, would provide Medicare beneficiaries with up to $500 annually to purchase CBD products. Supporters argue the program could expand access to alternative therapies for chronic pain, sleep disorders, and anxiety while helping reduce reliance on opioids and benzodiazepines.

But critics warn the policy risks bypassing the scientific framework that has governed American medicine for decades.

For more than a century, the United States has relied on a simple principle: if a company claims a product treats disease, it must prove that claim through rigorous scientific testing.

That process is overseen by the U.S. Food and Drug Administration and typically requires:

validated Chemistry, Manufacturing, and Controls (CMC) data

formal approval through a New Drug Application (NDA)